hsa-miR-217

ncRNA information

ncRNA name

hsa-miR-217

Specific or universal ncRNAs

Specific ncRNAs

Class

MicroRNA

Biomarker

No

Biomarker application

Upstream regulatory factors

Not available

Downstream target

KRAS

Cancer information

Cancer name

Lung Cancer

Cancer site

Lung

Treatment information

Treatment type

Chemotherapy

Drug

Cisplatin

Impact of wild-type ncRNA on chemotherapy resistance

Down

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

MiR-217 suppresses tumour development in lung cancer by targeting KRAS and enhances cell sensitivity to cisplatin.

Tissue resource

pairs of matched lung cancer and noncancerous tissue samples

lung cancer cell lines SPC-A-1

lung cancer cell lines A549

Experiment

qRT-PCR,Western blot,Luciferase reporter assay


Institute

the Cancer Institute and Hospital of Hebei

Country

China

Continent

Asia